Apo AI/CIII genomic polymorphisms predictive of atherosclerosis

A method for predicting the development of atherosclerosis in an individual human, which method comprises detecting the presence or absence of the "ApaI" polymorphism which is 5.4 kb 5' of the apoAI gene.

A method for predicting the development of atherosclerosis in an individual human, which method comprises detecting the presence of absence of the "PvuII" polymorphism which is in the first intron of the apoCIII gene.

The method of claim 15 which comprises detecting the presence or absence of a 0.87 kb DNA fragment of human genome which has been digested with PvuII, said fragment hybridizing with apoCIII probe or a substantially equivalent probe.

A method for predicting decreased susceptibility to atherosclerosis in an individual human which method comprises detecting the presence or absence of the "XmnI/7.2" polymorphism which is 3.7 kb 5' of the apoAI gene and the "MspI" polymorphism which is in the third intron of the apoAI gene.

A method of genetically identifying an individual, which method comprises assessing the presence or absence of at least one polymorphism by

• contacting a genomic DNA digest with apoAI probe or a substantial equivalent, wherein said digest is obtained by digesting the genome with an enzyme selected from the group consisting of XmnI, HgiAI, and PstI, or a subset thereof, and
• detecting the presence or absence of a diagnostic length DNA fragment which hybridizes to said probe.

A method of genetically identifying an individual, which method comprises assessing the presence or absence of at least one polymorphism by

• contacting a genomic DNA digest with p5'AI probe or a substantial equivalent, wherein said digest is obtained by digesting the genome with an enzyme selected from the group consisting of ApaI, XmnI, BglI, BstEII, PvuII, RsaI, StuI and TaqI or a subset thereof, and
• detecting the presence of absence of a diagnostic length DNA fragment which hybridizes to said probe.

A method of genetically identifying an individual which method comprises assessing the presence or absence of at least one polymorphism by

• contacting a genomic DNA digest with apoCIII probe or a substantial equivalent wherein said digest is obtained by digesting the genome with BanII, PvuII or both.

A method to detect the SstI/BanII polymorphism in the 4th exon of the gene which comprises digesting the genome with BanII and detecting a 1.0 and 0.8 kb fragment using apoCIII probe or a substantial equivalent.

A reagent kit useful in ascertaining individual human subjects having a propensity for disorders related to lipid transport and metabolism, which kit includes at least one probe selected from the group consisting of apoAI probe, p5'AI probe, and apoCIII probe, or their substantial equivalents, and at least one restriction enzyme selected from the group consisting of ApaI, XmnI, HgiAI, MspI, BanII, PvuII, BglI, BstEII, RsaI, StuI, and TaqI.